Bristol Lays Groundwork For First Dermatology Launch, Ahead Of TYK2 Inhibitor
The Company Will Begin Hiring A Sales Force
The company has not even filed the TYK2 inhibitor deucravacitinib for psoriasis, but Bristol will be a new player in a category dominated by entrenched rivals.
You may also be interested in...
Private Company Edition: Dyno’s first VC round will enable more deals for its novel AAV platform; Eikon pioneers new drug discovery technology. Also, Treeline’s early funding revealed at $211.7m; Capsida raised $140m from a VC round, AbbVie deal; and Affinia closed a $110m series B round.
Bristol Myers Squibb is struggling to restore Opdivo’s growth and COVID-19 sales impacts didn’t help in Q1. New indications are coming but new products, like Zeposia, are slow to add significant revenue.
The UK drug discovery specialist has made slow progress until now, but the Sanofi deal could yield a challenger in the competitive psoriasis field.